结直肠癌腹膜转移诊治专家共识(2025版)

Expert consensus on the diagnosis and treatment of colorectal cancer peritoneal metastasis (2025 edition)

  • 摘要: 结直肠癌是我国常见的恶性肿瘤之一,发病率和死亡率分别位居全部恶性肿瘤的第2位和第4位。转移和复发是导致患者死亡的主要原因。腹膜是结直肠癌常见的转移部位,仅次于肝转移和肺转移,但其预后远差于肝转移和肺转移。结直肠癌腹膜转移早期诊断困难,症状重,预后差,其规范化诊治对改善患者的预后和提高生命质量至关重要。中国医师协会结直肠肿瘤专业委员会基于循证医学证据,对《结直肠癌腹膜转移诊治中国专家共识(2022版)》进行修订,在结直肠癌腹膜转移的定义、诊断、治疗及预防等方面达成共识,以期指导和规范结直肠癌腹膜转移的诊疗,制订合理有效的综合治疗方案,延长结直肠癌腹膜转移患者生存时间并提高生命质量,提高我国结直肠癌的整体诊治水平。

     

    Abstract: Colorectal cancer (CRC) is one of the most common malignant tumors in China, ranking second in morbidity and fourth in mortality. Metastasis and recurrence are the leading causes of patient death, and the peritoneum is a frequent site of metastasis in CRC, second only to liver and lung metastases. However, the prognosis of peritoneal metastasis is much worse than hepatic and pulmonary metastasis. CRC peritoneal metastasis is challenging hard to diagnose early, presents with severe symptoms, and has a poor prognosis. It is crucial to emphasize standardized diagnosis and treatment for CRC peritoneal metastasis in order to improve outcome and enhance quality of life of patients. The Colorectal Cancer Professional Committee of Chinese Medical Doctor Association, based on evidence‑based medical evidence, has revised the "Chinese expert consensus on the diagnosis and treatment of colorectal cancer peritoneal metastasis (2022 edition)" and reached consensus on the definition, diagnosis, treatment, and prevention of CRC peritoneal metastasis, with the aim of guiding and standardizing the diagnosis and treatment of CRC peritoneal metastasis, developing reasonable and effective comprehensive treatment plans, prolonging survival time and improving quality of life for CRC peritoneal metastasis patients, and raising the overall level of diagnosis and treatment for CRC in China.

     

/

返回文章
返回